PPBT — PURPLE BIOTECH LTD.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1614744 ·
Last close
$1.51
Market Cap
$2.46M
52W High
$14.10
52W Low
$1.16
ADV30
2,659,897
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,299,000 | 441,000 | 14,166,000 | 5,236,000 | 1,953,000 |
| Mar 2026 | 0 | — | -2,251,000 | -86,000 | 14,417,000 | 5,567,000 | 4,753,000 |
| Dec 2025 | 0 | — | -2,963,000 | -23,545,000 | 17,572,000 | 8,717,000 | 7,913,000 |
| Sep 2025 | 0 | — | -1,367,000 | -1,303,000 | 39,061,000 | 9,592,000 | 6,246,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,799,000
Investing CF
$424,000
Financing CF
$6,166,000
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-386.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-171,167,000
Inventory
—
Receivables
$155,000
ST Investments
$859,000
EBIT TTM
$-26,066,000
Pretax Income TTM
$-26,125,000
Interest Exp TTM
$59,000
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,976,000 | -26,386,000 | 17,572,000 | 7,913,000 | 9,714,000 | -5,656,000 |
| Dec 2024 | 0 | -10,803,000 | -7,240,000 | 37,038,000 | 4,127,000 | 32,860,000 | -14,367,000 |
| Dec 2023 | 0 | -22,271,000 | -19,880,000 | 44,302,000 | 10,005,000 | 34,207,000 | -19,925,000 |
| Dec 2022 | 0 | -22,603,000 | -21,668,000 | 54,622,000 | 7,524,000 | 46,911,000 | -16,735,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.01
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.46 · call volume: 5 · put volume: 0
Expected Move to 2026-11-20:
±$1.45
(99.32%) —
implied range
$0.01 –
$2.91
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARTL | ARTELO BIOSCIENCES, INC. | $2.49M | $4.54 | — |
| BIXT | BIOXYTRAN, INC | $2.42M | $0.02 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $2.35M | $0.16 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.35M | $4.01 | — |
| VCNX | VACCINEX, INC. | $2.60M | $0.97 | — |
News headlines (Yahoo Finance, 1h cache)
Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection
2026-09-02 15:07 · Yahoo
Top Midday Gainers
2026-09-02 17:50 · Yahoo
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
2026-09-02 11:30 · Yahoo
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 11:00 · Yahoo
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
2026-04-27 11:00 · Yahoo
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
2026-04-23 11:00 · Yahoo
Purple Biotech Reports Second Quarter 2026 Financial Results
2026-08-07 11:00 · Yahoo
Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)
2026-06-11 14:38 · Yahoo
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
2026-06-11 11:00 · Yahoo
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
2026-01-07 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.